-0.08%
-4.19%
-4.52%
-11.60%
-22.83%
-34.65%
-57.43%
AI Spotlight on PRGO
Company Description
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed.The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International.The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America.
The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names.The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe.The company also offers contract manufacturing services.
Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Market Data
| Last Price | 24.91 |
| Change Percentage | -0.08% |
| Open | 24.98 |
| Previous Close | 24.93 |
| Market Cap ( Millions) | 3398 |
| Volume | 891496 |
| Year High | 33.46 |
| Year Low | 23.14 |
| M A 50 | 26.15 |
| M A 200 | 27.21 |
Financial Ratios
| FCF Yield | 4.57% |
| Dividend Yield | 4.54% |
| ROE | -3.34% |
| Debt / Equity | 104.10% |
| Net Debt / EBIDTA | 1194.99% |
| Price To Book | 0.73 |
| Price Earnings Ratio | -21.61 |
| Price To FCF | 21.89 |
| Price To sales | 0.76 |
| EV / EBITDA | 24.01 |
News
- Jan -31 - Perrigo to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025, Host Virtual Investor Day on February 28, 2025
- Jan -28 - Perrigo Paves The Way For Recovery With Margin Focus
- Jan -06 - Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer
- Nov -19 - Perrigo Company: Great Combination Of Future Growth With A Low Valuation
- Nov -11 - Perrigo (PRGO) International Revenue Performance Explored
- Nov -06 - Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated
- Nov -06 - Perrigo Company plc (PRGO) Q3 2024 Earnings Call Transcript
- Nov -06 - Perrigo (PRGO) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- Nov -06 - Perrigo (PRGO) Q3 Earnings and Revenues Lag Estimates
- Nov -06 - Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations
- Nov -04 - Perrigo to Report Q3 Earnings: Here's What to Expect
- Nov -01 - Perrigo Announces Quarterly Dividend
- Oct -23 - Perrigo to Release Third Quarter 2024 Financial Results on November 6, 2024
- Oct -15 - WNBA Star Napheesa Collier Joins Team Opill® for Candid Conversations on Women's Health
- Sep -26 - Perrigo Announces Good Start® and Dr. Browns® Brand Partnership and Launch of Infant Formula Portfolio
- Sep -17 - PERRIGO ANNOUNCES THE CLOSING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY
- Sep -12 - PERRIGO ANNOUNCES THE PRICING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY
- Sep -04 - Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary
- Aug -27 - Perrigo to Attend the Piper Sandler Growth Frontiers Conference
- Aug -19 - Perrigo Appoints David Ball to the Newly Created Position of Executive Vice President and Chief Brand and Digital Officer
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Consumer Self-Care Americas
Expected Growth : 4.5 %
What the company do ?
Consumer Self-Care Americas is a segment of Perrigo Company plc that focuses on over-the-counter healthcare products and nutritional supplements in the Americas region.
Why we expect these perspectives ?
Perrigo's Consumer Self-Care Americas segment growth of 4.5% is driven by increasing demand for self-care products, particularly in the OTC healthcare and vitamins, minerals, and supplements categories. Strong brand recognition, product innovation, and strategic acquisitions also contribute to growth. Additionally, the company's focus on e-commerce and digital marketing helps to expand its customer base and increase sales.
Segment n°2 -> Consumer Self-Care International
Expected Growth : 3.5 %
What the company do ?
Consumer Self-Care International is a segment of Perrigo Company plc that focuses on developing, manufacturing, and distributing over-the-counter (OTC) healthcare products and nutritional supplements.
Why we expect these perspectives ?
Perrigo's Consumer Self-Care International segment growth of 3.5% is driven by increasing demand for over-the-counter (OTC) healthcare products, expansion into emerging markets, and strategic acquisitions. Additionally, growing consumer awareness of self-care and wellness, coupled with an aging population, contribute to the segment's growth.
Perrigo Company Plc Products
| Product Range | What is it ? |
|---|---|
| Rx Pharmaceuticals | Perrigo's Rx Pharmaceuticals segment develops, manufactures, and markets prescription pharmaceuticals, including topical and oral products, for the treatment of various health conditions. |
| Consumer Self-Care | Perrigo's Consumer Self-Care segment offers a range of over-the-counter (OTC) healthcare products, including vitamins, minerals, and nutritional supplements. |
| Nutritionals | Perrigo's Nutritionals segment provides infant formula, baby food, and other nutritional products for infants and toddlers. |
| Active Pharmaceutical Ingredients (APIs) | Perrigo's API segment develops and manufactures active pharmaceutical ingredients for use in pharmaceutical products. |
Perrigo Company plc's Porter Forces
Threat Of Substitutes
Perrigo Company plc operates in the pharmaceutical industry, where substitutes are available, but the company's strong brand presence and product offerings mitigate the threat.
Bargaining Power Of Customers
Perrigo Company plc's customers are largely retailers and wholesalers, who have limited bargaining power due to the company's strong market position and diversified product portfolio.
Bargaining Power Of Suppliers
Perrigo Company plc relies on a diverse supplier base, which reduces the bargaining power of individual suppliers, but the company still faces some pressure from suppliers of critical raw materials.
Threat Of New Entrants
The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and capital requirements, which limits the threat of new entrants to Perrigo Company plc's business.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established players, which increases the intensity of rivalry and competition for Perrigo Company plc.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 46.07% |
| Debt Cost | 7.11% |
| Equity Weight | 53.93% |
| Equity Cost | 7.11% |
| WACC | 7.11% |
| Leverage | 85.43% |
Perrigo Company plc : Quality Control
Perrigo Company plc passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| DMP.DE | Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel … |
| ALM.MC | Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for … |
| SOBI.ST | Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North … |
| SFZN.SW | Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral … |
| ALVO | Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Dermapharm Holding
A-Score
1-Year Total Return ->
🥈
Almirall
A-Score
1-Year Total Return ->
🥉
Siegfried Holding
A-Score
1-Year Total Return ->
4
Sobi
A-Score
1-Year Total Return ->
5
Alvotech
A-Score
1-Year Total Return ->
6
